Glucagon-like peptide-1(7–37) has a larger volume of distribution than glucagon-like peptide-1(7–36)amide in dogs and is degraded more quickly in vitro ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-03

AUTHORS

L. Pridal, C. F. Deacon, O. Kirk, J. V. Christensen, R. D. Carr, J. J. Holst

ABSTRACT

The pharmacokinetic properties of glucagon-like peptide-1(7-36)amide (GLP-1(7-37) were compared. Four beagle dogs received on 4 separate occasions s.c. bolus doses of 50 micrograms/kg, and 2 min i.v. infusions of 50 micrograms/kg of each peptide. The plasma immunoreactivity of GLP-1 (P-GLP-1-IR) was measured by a sandwich enzyme-linked immunosorbent assay (ELISA). After i.v. infusion, the plasma half-life in the first-phase was 2.1 +/- 0.1 and 2.4 +/- 0.3 min, in the final-phase 68 +/- 6 and 81 +/- 3 min, the total plasma clearance 25 +/- 3 and 22 +/- 4 ml/kg.min, the volume of distribution at steady state 0.16 +/- 0.02 and 0.84 +/- 0.24 l/kg, and the mean residence time 6.2 +/- 0.3 and 36 +/- 5 min for GLP-1(7-36)amide and GLP-1(7-37), respectively. After s.c. administration, the maximum plasma concentration was reached after 15 +/- 5 and 19 +/- 4 min and the absolute bioavailability was 48 +/- 7 and 49 +/- 13% for GLP-1(7-36)amide and GLP-1(7-37), respectively. P-GLP-1-IR, measured by a radioimmunoassay (RIA), was considerably higher than when measured by ELISA. This discrepancy was due to cross-reactivity with metabolites of the parent peptide. The plasma degradation was studied in vitro in dog plasma at 37 degrees C, and the half-lives were found to be 61 +/- 9 and 132 +/- 16 min for GLP-1(7-36)amide and GLP-1(7-37), respectively (n = 6). Bacitracin inhibited the degradation of both peptides. More... »

PAGES

51-59

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf03190278

DOI

http://dx.doi.org/10.1007/bf03190278

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1006004995

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/8839678


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0202", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Atomic, Molecular, Nuclear, Particle and Plasma Physics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/02", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Physical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dogs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gastrointestinal Hormones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucagon-Like Peptide 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "In Vitro Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Subcutaneous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peptides", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Novo Nordisk (Denmark)", 
          "id": "https://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk, Diabetes Discovery, 6B. S. 74, Novo Nordisk A/S, 2880, Bagsvoerd, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pridal", 
        "givenName": "L.", 
        "id": "sg:person.0676160400.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676160400.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Copenhagen", 
          "id": "https://www.grid.ac/institutes/grid.5254.6", 
          "name": [
            "Department of Medical Physiology, Panum Institute, University of Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Deacon", 
        "givenName": "C. F.", 
        "id": "sg:person.01026605564.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026605564.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk (Denmark)", 
          "id": "https://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk, Diabetes Discovery, 6B. S. 74, Novo Nordisk A/S, 2880, Bagsvoerd, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kirk", 
        "givenName": "O.", 
        "id": "sg:person.01245041336.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245041336.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk (Denmark)", 
          "id": "https://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk, Diabetes Discovery, 6B. S. 74, Novo Nordisk A/S, 2880, Bagsvoerd, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Christensen", 
        "givenName": "J. V.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk (Denmark)", 
          "id": "https://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk, Diabetes Discovery, 6B. S. 74, Novo Nordisk A/S, 2880, Bagsvoerd, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carr", 
        "givenName": "R. D.", 
        "id": "sg:person.01225665616.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225665616.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Copenhagen", 
          "id": "https://www.grid.ac/institutes/grid.5254.6", 
          "name": [
            "Department of Medical Physiology, Panum Institute, University of Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Holst", 
        "givenName": "J. J.", 
        "id": "sg:person.0632007550.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632007550.38"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/0731-7085(95)01312-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006405665"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0167-0115(92)90152-k", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023676429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-5491.1995.tb00526.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033779050"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-5491.1995.tb00526.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033779050"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0014-2999(96)00795-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047097301"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000201061", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051123234"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-2007-1001766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057476402"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jc.80.3.952", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064298136"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jcem.80.3.7883856", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064319418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.42.5.658", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070737061"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.44.9.1126", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070737650"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diabetes.42.5.658", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070742568"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diabetes.44.9.1126", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070743106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00429088", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075579500", 
          "https://doi.org/10.1007/bf00429088"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00429088", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075579500", 
          "https://doi.org/10.1007/bf00429088"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077287146", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082619552", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082660071", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1996-03", 
    "datePublishedReg": "1996-03-01", 
    "description": "The pharmacokinetic properties of glucagon-like peptide-1(7-36)amide (GLP-1(7-37) were compared. Four beagle dogs received on 4 separate occasions s.c. bolus doses of 50 micrograms/kg, and 2 min i.v. infusions of 50 micrograms/kg of each peptide. The plasma immunoreactivity of GLP-1 (P-GLP-1-IR) was measured by a sandwich enzyme-linked immunosorbent assay (ELISA). After i.v. infusion, the plasma half-life in the first-phase was 2.1 +/- 0.1 and 2.4 +/- 0.3 min, in the final-phase 68 +/- 6 and 81 +/- 3 min, the total plasma clearance 25 +/- 3 and 22 +/- 4 ml/kg.min, the volume of distribution at steady state 0.16 +/- 0.02 and 0.84 +/- 0.24 l/kg, and the mean residence time 6.2 +/- 0.3 and 36 +/- 5 min for GLP-1(7-36)amide and GLP-1(7-37), respectively. After s.c. administration, the maximum plasma concentration was reached after 15 +/- 5 and 19 +/- 4 min and the absolute bioavailability was 48 +/- 7 and 49 +/- 13% for GLP-1(7-36)amide and GLP-1(7-37), respectively. P-GLP-1-IR, measured by a radioimmunoassay (RIA), was considerably higher than when measured by ELISA. This discrepancy was due to cross-reactivity with metabolites of the parent peptide. The plasma degradation was studied in vitro in dog plasma at 37 degrees C, and the half-lives were found to be 61 +/- 9 and 132 +/- 16 min for GLP-1(7-36)amide and GLP-1(7-37), respectively (n = 6). Bacitracin inhibited the degradation of both peptides.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf03190278", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1085481", 
        "issn": [
          "0378-7966", 
          "2107-0180"
        ], 
        "name": "European Journal of Drug Metabolism and Pharmacokinetics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "name": "Glucagon-like peptide-1(7\u201337) has a larger volume of distribution than glucagon-like peptide-1(7\u201336)amide in dogs and is degraded more quickly in vitro by dog plasma", 
    "pagination": "51-59", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1c9add3d2dd16813980b369703424e449703c4aa02ad596bfcc6ddc6aec8db0a"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "8839678"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7608491"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf03190278"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1006004995"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf03190278", 
      "https://app.dimensions.ai/details/publication/pub.1006004995"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:49", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000350_0000000350/records_77557_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2FBF03190278"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf03190278'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf03190278'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf03190278'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf03190278'


 

This table displays all metadata directly associated to this object as RDF triples.

192 TRIPLES      21 PREDICATES      55 URIs      31 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf03190278 schema:about N142e4ddb14a84a7396fed2cddbc3c085
2 N307d0f9c7ab241ee891e8054b3eb3f95
3 N378edd60ec264e1685018ff49d6765a9
4 N411d26f47b564402a7c86e971ef1d057
5 N6589180eb78f4e37bbab1cf80af2b076
6 N6c08bd9da6404d6fb9762b4df353c01c
7 Na15392caf44343858d21cc81a878b69e
8 Na3de8ad0964a44c0b51ba7bbf9eaa79b
9 Ncc4ad19ba9dd44228402a5c7d8194d74
10 Nd242e8fbd3b147ad8d30952c7b6cccd1
11 anzsrc-for:02
12 anzsrc-for:0202
13 schema:author Nddb5b1ed771841faa3c9bb756da49952
14 schema:citation sg:pub.10.1007/bf00429088
15 https://app.dimensions.ai/details/publication/pub.1077287146
16 https://app.dimensions.ai/details/publication/pub.1082619552
17 https://app.dimensions.ai/details/publication/pub.1082660071
18 https://doi.org/10.1016/0167-0115(92)90152-k
19 https://doi.org/10.1016/0731-7085(95)01312-9
20 https://doi.org/10.1016/s0014-2999(96)00795-9
21 https://doi.org/10.1055/s-2007-1001766
22 https://doi.org/10.1111/j.1464-5491.1995.tb00526.x
23 https://doi.org/10.1159/000201061
24 https://doi.org/10.1210/jc.80.3.952
25 https://doi.org/10.1210/jcem.80.3.7883856
26 https://doi.org/10.2337/diab.42.5.658
27 https://doi.org/10.2337/diab.44.9.1126
28 https://doi.org/10.2337/diabetes.42.5.658
29 https://doi.org/10.2337/diabetes.44.9.1126
30 schema:datePublished 1996-03
31 schema:datePublishedReg 1996-03-01
32 schema:description The pharmacokinetic properties of glucagon-like peptide-1(7-36)amide (GLP-1(7-37) were compared. Four beagle dogs received on 4 separate occasions s.c. bolus doses of 50 micrograms/kg, and 2 min i.v. infusions of 50 micrograms/kg of each peptide. The plasma immunoreactivity of GLP-1 (P-GLP-1-IR) was measured by a sandwich enzyme-linked immunosorbent assay (ELISA). After i.v. infusion, the plasma half-life in the first-phase was 2.1 +/- 0.1 and 2.4 +/- 0.3 min, in the final-phase 68 +/- 6 and 81 +/- 3 min, the total plasma clearance 25 +/- 3 and 22 +/- 4 ml/kg.min, the volume of distribution at steady state 0.16 +/- 0.02 and 0.84 +/- 0.24 l/kg, and the mean residence time 6.2 +/- 0.3 and 36 +/- 5 min for GLP-1(7-36)amide and GLP-1(7-37), respectively. After s.c. administration, the maximum plasma concentration was reached after 15 +/- 5 and 19 +/- 4 min and the absolute bioavailability was 48 +/- 7 and 49 +/- 13% for GLP-1(7-36)amide and GLP-1(7-37), respectively. P-GLP-1-IR, measured by a radioimmunoassay (RIA), was considerably higher than when measured by ELISA. This discrepancy was due to cross-reactivity with metabolites of the parent peptide. The plasma degradation was studied in vitro in dog plasma at 37 degrees C, and the half-lives were found to be 61 +/- 9 and 132 +/- 16 min for GLP-1(7-36)amide and GLP-1(7-37), respectively (n = 6). Bacitracin inhibited the degradation of both peptides.
33 schema:genre research_article
34 schema:inLanguage en
35 schema:isAccessibleForFree false
36 schema:isPartOf Nbba624650a804e24b7a9ddcd597a76f4
37 Ndbbc9767a8c8498c9426191aecb4bccd
38 sg:journal.1085481
39 schema:name Glucagon-like peptide-1(7–37) has a larger volume of distribution than glucagon-like peptide-1(7–36)amide in dogs and is degraded more quickly in vitro by dog plasma
40 schema:pagination 51-59
41 schema:productId N3d8b7f987ed045d49d4dbb161057c347
42 N4fd388dbf0534e00862f1db1ec6c80f7
43 N7c3d39cc3fe14dfa8d38750cb51af6b7
44 Na25e9393382d4fcc860f04c07eaf9b6e
45 Na2c8bbdb9e56459b8982a9f2de17bdb1
46 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006004995
47 https://doi.org/10.1007/bf03190278
48 schema:sdDatePublished 2019-04-11T10:49
49 schema:sdLicense https://scigraph.springernature.com/explorer/license/
50 schema:sdPublisher Ne65c66dd48ec43768b4b715f25ae17a5
51 schema:url http://link.springer.com/10.1007%2FBF03190278
52 sgo:license sg:explorer/license/
53 sgo:sdDataset articles
54 rdf:type schema:ScholarlyArticle
55 N0b58322c203e4f00a05f424e7c7c1fc8 rdf:first sg:person.01225665616.44
56 rdf:rest N4837434e0c0648c5b1695206114d1600
57 N142e4ddb14a84a7396fed2cddbc3c085 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Female
59 rdf:type schema:DefinedTerm
60 N1bb5c9a4cb4140708614a8c79b0eeb1c rdf:first sg:person.01245041336.14
61 rdf:rest N87b6771fc42a4666aadd268ed1e93749
62 N307d0f9c7ab241ee891e8054b3eb3f95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Injections, Intravenous
64 rdf:type schema:DefinedTerm
65 N378edd60ec264e1685018ff49d6765a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Animals
67 rdf:type schema:DefinedTerm
68 N3d8b7f987ed045d49d4dbb161057c347 schema:name readcube_id
69 schema:value 1c9add3d2dd16813980b369703424e449703c4aa02ad596bfcc6ddc6aec8db0a
70 rdf:type schema:PropertyValue
71 N411d26f47b564402a7c86e971ef1d057 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Gastrointestinal Hormones
73 rdf:type schema:DefinedTerm
74 N4837434e0c0648c5b1695206114d1600 rdf:first sg:person.0632007550.38
75 rdf:rest rdf:nil
76 N4fd388dbf0534e00862f1db1ec6c80f7 schema:name pubmed_id
77 schema:value 8839678
78 rdf:type schema:PropertyValue
79 N6589180eb78f4e37bbab1cf80af2b076 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Dogs
81 rdf:type schema:DefinedTerm
82 N6c08bd9da6404d6fb9762b4df353c01c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Injections, Subcutaneous
84 rdf:type schema:DefinedTerm
85 N7c3d39cc3fe14dfa8d38750cb51af6b7 schema:name nlm_unique_id
86 schema:value 7608491
87 rdf:type schema:PropertyValue
88 N87b6771fc42a4666aadd268ed1e93749 rdf:first Nacfecd5224f54d36a2195eb63065aeed
89 rdf:rest N0b58322c203e4f00a05f424e7c7c1fc8
90 Na15392caf44343858d21cc81a878b69e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Glucagon-Like Peptide 1
92 rdf:type schema:DefinedTerm
93 Na25e9393382d4fcc860f04c07eaf9b6e schema:name doi
94 schema:value 10.1007/bf03190278
95 rdf:type schema:PropertyValue
96 Na2c8bbdb9e56459b8982a9f2de17bdb1 schema:name dimensions_id
97 schema:value pub.1006004995
98 rdf:type schema:PropertyValue
99 Na3de8ad0964a44c0b51ba7bbf9eaa79b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name In Vitro Techniques
101 rdf:type schema:DefinedTerm
102 Nacfecd5224f54d36a2195eb63065aeed schema:affiliation https://www.grid.ac/institutes/grid.425956.9
103 schema:familyName Christensen
104 schema:givenName J. V.
105 rdf:type schema:Person
106 Nb4b420662f6249ffba643290e5463054 rdf:first sg:person.01026605564.74
107 rdf:rest N1bb5c9a4cb4140708614a8c79b0eeb1c
108 Nbba624650a804e24b7a9ddcd597a76f4 schema:issueNumber 1
109 rdf:type schema:PublicationIssue
110 Ncc4ad19ba9dd44228402a5c7d8194d74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Peptides
112 rdf:type schema:DefinedTerm
113 Nd242e8fbd3b147ad8d30952c7b6cccd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Male
115 rdf:type schema:DefinedTerm
116 Ndbbc9767a8c8498c9426191aecb4bccd schema:volumeNumber 21
117 rdf:type schema:PublicationVolume
118 Nddb5b1ed771841faa3c9bb756da49952 rdf:first sg:person.0676160400.40
119 rdf:rest Nb4b420662f6249ffba643290e5463054
120 Ne65c66dd48ec43768b4b715f25ae17a5 schema:name Springer Nature - SN SciGraph project
121 rdf:type schema:Organization
122 anzsrc-for:02 schema:inDefinedTermSet anzsrc-for:
123 schema:name Physical Sciences
124 rdf:type schema:DefinedTerm
125 anzsrc-for:0202 schema:inDefinedTermSet anzsrc-for:
126 schema:name Atomic, Molecular, Nuclear, Particle and Plasma Physics
127 rdf:type schema:DefinedTerm
128 sg:journal.1085481 schema:issn 0378-7966
129 2107-0180
130 schema:name European Journal of Drug Metabolism and Pharmacokinetics
131 rdf:type schema:Periodical
132 sg:person.01026605564.74 schema:affiliation https://www.grid.ac/institutes/grid.5254.6
133 schema:familyName Deacon
134 schema:givenName C. F.
135 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026605564.74
136 rdf:type schema:Person
137 sg:person.01225665616.44 schema:affiliation https://www.grid.ac/institutes/grid.425956.9
138 schema:familyName Carr
139 schema:givenName R. D.
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225665616.44
141 rdf:type schema:Person
142 sg:person.01245041336.14 schema:affiliation https://www.grid.ac/institutes/grid.425956.9
143 schema:familyName Kirk
144 schema:givenName O.
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245041336.14
146 rdf:type schema:Person
147 sg:person.0632007550.38 schema:affiliation https://www.grid.ac/institutes/grid.5254.6
148 schema:familyName Holst
149 schema:givenName J. J.
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632007550.38
151 rdf:type schema:Person
152 sg:person.0676160400.40 schema:affiliation https://www.grid.ac/institutes/grid.425956.9
153 schema:familyName Pridal
154 schema:givenName L.
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676160400.40
156 rdf:type schema:Person
157 sg:pub.10.1007/bf00429088 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075579500
158 https://doi.org/10.1007/bf00429088
159 rdf:type schema:CreativeWork
160 https://app.dimensions.ai/details/publication/pub.1077287146 schema:CreativeWork
161 https://app.dimensions.ai/details/publication/pub.1082619552 schema:CreativeWork
162 https://app.dimensions.ai/details/publication/pub.1082660071 schema:CreativeWork
163 https://doi.org/10.1016/0167-0115(92)90152-k schema:sameAs https://app.dimensions.ai/details/publication/pub.1023676429
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1016/0731-7085(95)01312-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006405665
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1016/s0014-2999(96)00795-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047097301
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1055/s-2007-1001766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057476402
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1111/j.1464-5491.1995.tb00526.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033779050
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1159/000201061 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051123234
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1210/jc.80.3.952 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064298136
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1210/jcem.80.3.7883856 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064319418
178 rdf:type schema:CreativeWork
179 https://doi.org/10.2337/diab.42.5.658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070737061
180 rdf:type schema:CreativeWork
181 https://doi.org/10.2337/diab.44.9.1126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070737650
182 rdf:type schema:CreativeWork
183 https://doi.org/10.2337/diabetes.42.5.658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070742568
184 rdf:type schema:CreativeWork
185 https://doi.org/10.2337/diabetes.44.9.1126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070743106
186 rdf:type schema:CreativeWork
187 https://www.grid.ac/institutes/grid.425956.9 schema:alternateName Novo Nordisk (Denmark)
188 schema:name Novo Nordisk, Diabetes Discovery, 6B. S. 74, Novo Nordisk A/S, 2880, Bagsvoerd, Denmark
189 rdf:type schema:Organization
190 https://www.grid.ac/institutes/grid.5254.6 schema:alternateName University of Copenhagen
191 schema:name Department of Medical Physiology, Panum Institute, University of Copenhagen, Denmark
192 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...